Vonova develops minimally invasive neurotechnology platforms designed to access the brain via the vascular system rather than open surgery. The company’s flagship platform, Cerebro, provides endovascular access to neural tissue to support therapeutic intervention without cranial drilling. Its approach focuses on reducing surgical risk while enabling precise delivery of therapies to targeted brain regions. Vonova positions its technology within regulated clinical and neurosurgical care contexts.

The technology uses catheter-based endovascular techniques to navigate blood vessels and reach specific brain regions. This access allows delivery of therapeutics, stimulation, or sensing devices directly to neural tissue while minimizing trauma associated with traditional craniotomy. The system emphasizes safety, accuracy, and compatibility with chronic or repeatable interventions. Cerebro’s design supports integration with emerging minimally invasive neuromodulation and drug delivery approaches.

Vonova targets neurological disorders that may benefit from direct brain intervention, including movement disorders, neurodegenerative disease, and epilepsy. The platform is intended for use by trained clinicians within specialized hospital or surgical settings. Its positioning reflects broader efforts to expand minimally invasive approaches for neurosurgical therapy and precise brain access.